Brasada Capital Management’s Emergent Biosolutions EBS Stock Holding History

Brasada Capital Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,500	Closed	-$258K	–	148
2020 Q3	$258K	Buy	2,500 +500	+25%	+$53.9K	0.07%	129
2020 Q2	$158K	Buy	+2,000	New	+$149K	0.04%	134
2019 Q1	–	Sell	-6,000	Closed	-$356K	–	186
2018 Q4	$356K	Hold	6,000	–	–	0.12%	123
2018 Q3	$395K	Buy	6,000 +1,000	+20%	+$58.4K	0.11%	143
2018 Q2	$252K	Hold	5,000	–	–	0.08%	165
2018 Q1	$263K	Sell	5,000 -6,000	-55%	-$299K	0.08%	160
2017 Q4	$511K	Buy	+11,000	New	+$463K	0.17%	97

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Brasada Capital Management's EBS Position: Q4 2020 in Review

Brasada Capital Management sold out of Emergent Biosolutions (EBS) in Q4 2020, closing a stake of 2,500 shares — an estimated $258K sold.

Brasada Capital Management first reported a position in EBS in Q4 2017 and held it in 7 quarters. The position peaked at $511K in Q4 2017. 353 funds tracked by Wall St. Rank hold EBS as of Q4 2020.

Brasada Capital Management reported no remaining Emergent Biosolutions position as of Q4 2020 after selling out during the quarter.
Brasada Capital Management sold 2,500 Emergent Biosolutions shares in Q4 2020, an estimated $258K.
Brasada Capital Management first reported a position in Emergent Biosolutions in Q4 2017 and held it in 7 quarters.
Brasada Capital Management's Emergent Biosolutions position peaked at $511K in Q4 2017.
353 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2020.

Based on Brasada Capital Management's 13F filing for Q4 2020, filed 5 Feb 2021.